From GlobeNewswire: 2025-04-23 20:00:00

HUTCHMED announces new data on compounds savolitinib, fruquintinib, and surufatinib to be presented at AACR Annual Meeting 2025. Studies include targeting KEAP1/NRF2 signaling in NSCLC, clearance of plasma EGFRm in NSCLC patients post-osimertinib, and brain exposure of [11C]savolitinib in healthy volunteers. Investigator-initiated studies focus on treatment regimens for metastatic colorectal cancer and the efficacy of surufatinib in advanced grade 3 neuroendocrine tumors. Savolitinib, a selective MET inhibitor, is approved in China for NSCLC with MET exon 14 skipping alteration and is under clinical development for multiple tumor types. Combination therapy with savolitinib and TAGRISSO shows promise in patients with MET aberrations post-EGFR TKI treatment. Positive data from the SACHI randomized Phase III trial has led to the filing of a second New Drug Application in China. The SAVANNAH single-arm Phase II study demonstrated high objective response rates with consistent safety results at the European Lung Cancer Congress. The SAFFRON Phase III trial is progressing, evaluating the combination of savolitinib and TAGRISSO® for NSCLC treatment. Additionally, the Fast Track Designation was received for savolitinib and TAGRISSO® in the US. HUTCHMED is an innovative biopharmaceutical company focused on targeted therapies for cancer and immunological diseases. Forward-looking statements were made regarding fruquintinib, savolitinib, and surufatinib. Researchers have found that MET inhibitors show promise in treating EGFR TKI-resistant lung cancer, according to a study published in the Journal of Hematology & Oncology. The study, led by Wang Q et al., highlights the potential for targeted therapy in patients with this type of cancer. This research could lead to new treatment options for individuals who have not responded to traditional EGFR TKI therapy. The findings offer hope for improved outcomes and quality of life for those affected by this challenging form of lung cancer. 1. The stock market saw a significant increase today, with the S&P 500 reaching a new record high of 4,200 points. This surge was fueled by strong earnings reports from major tech companies, such as Apple and Microsoft.

2. In international news, the United Nations reported a sharp rise in civilian casualties in Afghanistan, with over 1,700 deaths and injuries recorded in the first three months of the year. This increase has been attributed to the ongoing conflict between government forces and the Taliban.

3. On the economic front, the US economy added 266,000 jobs in April, falling short of expectations. The unemployment rate also rose slightly to 6.1%, with analysts pointing to challenges in the labor market recovery.

4. In health news, the CDC announced that fully vaccinated individuals no longer need to wear masks outdoors or indoors in most settings. This update comes as a result of the declining number of COVID-19 cases and the effectiveness of the vaccines in preventing transmission.

5. Lastly, in sports news, the NBA playoffs are in full swing, with several teams securing spots in the second round. The Brooklyn Nets and the Los Angeles Lakers are among the top contenders, with fans eagerly anticipating the matchups to come.



Read more at GlobeNewswire: HUTCHMED Highlights Data to be Presented at